BioSpace News Archive

The global single cell analysis market size was evaluated at US$ 3.5 billion in 2023 and is expected to grow at a CAGR of 16.82%, to reach around US$ 16.57 billion by 2033.

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024.

Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.

HUTCHMED Limited announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.

Bot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software to the Urologist community at the recent AUA meeting in San Antonio, Texas and received rave reviews.

Ionis Pharmaceuticals, Inc. today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential.

CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership team.

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study.